Please assess the completion status of the following clinical trial:

Trial Title: Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or non-pregnant female adult ≥18 years of age at time of enrollment.~2. has laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other commercial or public health assay (result of the PCR is not necessary for inclusion, but has to approved latest within 48-72 hours after registration)~3. Willingness of men and women of childbearing potential to use highly effective contraceptive methods by abstinence or by using at least two contraceptive methods from the date of consent to the end of the study~4. severe lung disease as defined by following:~   1. Recent intubation~  2. Requirement of invasive ventilation moderate to severe pulmonary oxygen exchange disturbance as defined by (PaO2/FiO2) ≤ 200 mmHg at a PEEP ≥ 5mm H2O~  3. Serum LDH \> 283 U/l~  4. Ferritin above normal value~  5. CT-scan: pulmonary infiltration compatible with Covid-19 disease~5. Patient or patient´s representative must provide written informed consent (and assent if applicable) before any study assessment is performed.~Exclusion Criteria:~1. Uncontrolled HIV infection~2. Active tuberculosis (result of positive tuberculosis infection is not necessary for exclusion, but has to approved later on during patient´s intervention)~3. Chronic kidney disease requiring dialysis~4. ALT/AST \> 5 times the upper limit of normal.~5. Pregnancy or breast feeding.~6. Allergy to study medication~7. Simultaneous participation in another clinical trial with an experimental treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib treatment (Type: EXPERIMENTAL): Ruxolitinib will be administered p.o. or by gavage feeding for max 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).